Ethicon Advanced Wound Closure Products to reduce Surgical Site Infection risk – SSI – Zero Starts With One
Ethicon Advanced Wound Closure Products to reduce Surgical Site Infection risk – SSI – Zero Starts With One

Watch real stories about real SSI events

More stories

Hear from patients and experts

James Ban US Marine patient story on facing surgical site infection – SSI – following back surgery after active duty

Real Patient Story: James Bane

James was a US Marine who survived several roadside bombs during active duty only to be afflicted with a life-changing SSI following routine back surgery years later. Hear his important challenge to medical professionals.

Alicia Cole Patient Story on facing surgical site infection – SSI – following fibroid removal surgery

Real Patient Story: Alicia Cole

Alicia was the picture of health when she underwent fibroid removal in anticipation of starting a family. She left surgery with an SSI necessitating 7 surgeries, 9 blood transfusions, and a 2-month hospital stay. Hear her story and her advice to surgeons.

Pierre Theodore, MD Cardiothoracic Oncology Surgeon Story on misconceptions on surgical site infection risk - SSI

Cardiothoracic Surgeon Story: Pierre Theodore, MD

Vice President, Medical Affairs, Johnson & Johnson Global Public Health Adjunct Professor of Cardiac Surgery, Stanford University
Dr. Theodore shares his unique perspective as a surgeon–and as a patient who experienced an SSI. Hear him debunk some common misconceptions about SSI risk and share advice on how surgeons can reduce SSI risk for their patients.

Anthonia Chen, MD Orthopaedic Surgeon Story on reducing surgical site infection risk - SSIs

Orthopedic Surgeon Story: Antonia Chen, MD

Hip & Knee Arthroplasty Surgeon, Director of Research – Brigham & Women’s Hospital
Associate Professor – Harvard Medical School
Dr. Chen shares how devastating SSIs can be for orthopedic patients and best practices that surgeons can follow to reduce risk. See how she’s leveraged Ethicon’s Advanced Wound Closure products to improve patient outcomes.

Ethicon Advanced Wound Closure Products – Plus Antibacterial Sutures – behind the science story on development and efficacy

Behind the Science: The Invention and Evidence for Ethicon’s Novel Technologies

Hear from the inventors of Plus Antibacterial Sutures on the development of this game-changing technology and a wound care expert on the evidence for Plus Sutures, STRATAFIX™ Knotless Tissue Control Device, and DERMABOND® PRINEO® Skin Closure System.

SSIs can have catastrophic consequences

Single Surgical site infection – SSI – can cost up to thirty-nine thousand dollars – economic information from Ethicon

SSIs are common and costly

In the US, there are 780,000+ cases per year, costing an additional $3.5-$10 billion. SSIs occur in 2%-5% of patients undergoing surgery—approximately 160,000 to 300,000 each year in the US.3-5

Surgical Site Infection information from Ethicon – Readmissions 5x more likely – patients 2x as likely to die

SSIs can be disfiguring or even fatal

Patients with SSIs are 5 times more likely to be readmitted to the hospital and 2 times more likely to die.3

Surgical site infection information from Ethicon – 67% of all SSIs confined to the incision

Bacterial colonization of the suture is a known SSI risk factor

Sutures–like all implanted materials–can be a nidus for SSI because they reduce the amount of bacteria needed to cause infection. Plus Sutures are the only intervention that can address bacterial colonization of the suture. If you’re not using antibacterial sutures, you’re not addressing this risk factor.6,7

Reducing surgical site infections (SSIs) can provide cost savings

SSI prevention is key in cutting costs

Economic analysis estimated that payers would avoid $1036-$1170 in superficial and deep-incisional SSI-related costs per patient over 12 months if triclosan-coated sutures were used in colorectal surgery vs traditional closure.8,9,27,†

Featured Wound Closure Products

Advanced Wound Closure products from Ethicon to reduce SSI risk – Plus Antibacterial Sutures

Plus Antibacterial Sutures

Plus Sutures are the only triclosan-coated sutures commercially available worldwide—and are backed by a large body of evidence and endorsed by a growing number of health authorities around the world. Meta-analysis showed a 28% reduction in SSI risk with the use of triclosan-coated sutures.7,8,10-21,28,29

Advanced Wound Closure products from Ethicon to reduce SSI risk – STRATAFIX barbed suture

STRATAFIX™ Knotless Tissue Control Devices

STRATAFIX™ is the only commercially available barbed suture with triclosan. And like Plus Suture, it is backed by a large body of evidence and health authority endorsements. Meta-analysis showed a 28% reduction in SSI risk with the use of triclosan-coated sutures.7-22,28-31

Advanced Wound Closure products from Ethicon to reduce SSI risk – DERMABOND Prineo Skin Closure System

DERMABOND® PRINEO® Skin Closure System

DERMABOND PRINEO System creates a watertight seal, creating a barrier to water and bacteria entering the wound. The microbial barrier is proven 99% effective through 72 hours in vitro.32 DERMABOND PRINEO System is demonstrated in vitro to kill 99.99% of bacteria (MRSA, MRSE, and E. coli) on direct contact.23-26,33

Advanced Wound Closure products from Ethicon to reduce SSI risk – view our portfolio

Ethicon Wound Closure Portfolio

Ethicon is the global leader in wound closure technology, each innovation designed to improve efficiency for surgeons and hospitals and outcomes for patients.

References

*As shown in coronary artery bypass surgery.

† Median costs estimated to be avoided per patient for commercial payers and Medicare were $1170 (95% CI, $146–$4884) and $1036 (95% CI, $111–$4823), respectively. 

  1. Plus Suture Cost Analysis. 2019. Ethicon, Inc. 
  2. de Lissovoy G, Pan F, Patkar A, et al. Surgical Site Infection Incidence and Burden Assessment Using Multi-institutional Real-world Data. Poster presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress; November 5-8, 2011; Madrid, Spain. 
  3. World Health Organization. WHO Guidelines for Safe Surgery, 2009. 
  4. Thompson KM, Oldenberg WA, Deschamps C, Rupp WC, Smith CD. Chasing zero: The drive to eliminate surgical site infections. Ann Surg. 2011;254:430-437. 
  5. Anderson DJ, Podgorny K, Berrios-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(6):605-627. 
  6. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20(4):247-278. 
  7. Edmiston CE, Seabrook GR, Goheen MP, et al. Bacterial adherence to surgical sutures: can antibacterial-coated sutures reduce the risk of microbial contamination? J Am Col Surg. 2006;203:481-489. 
  8. Edmiston CE, Daoud FC, Leaper D. Is there an evidence-based argument for embracing an antimicrobial (triclosan)-coated suture technology to reduce the risk for surgical-site infections?: A meta-analysis. Surgery. 2013;154:89-100. 
  9. Leaper DJ, Holy CE, Spencer M, Chitnis A, Hogan A, Wright GWJ, Chen BPH, Edmiston CE, Assessment of the Risk and Economic Burden of Surgical Site Infection Following Colorectal Surgery Using a US Longitudinal Database: Is There a Role for Innovative Antimicrobial Wound Closure Technology to Reduce the Risk of Infection? Diseases of the Colon & Rectum 2020; DOI:10.1097/DCR.0000000000001799 
  10. de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg. 2017;104(2):e118-e133. 
  11. Leaper DJ, Edmiston CE Jr, Holy CE. Meta-analysis of the potential economic impact following introduction of absorbable antimicrobial sutures. Br J Surg. 2017;104(2):e134-e144. 
  12. Apisarnthanarak A, Singh N, Bandong AN, et al. Triclosan-coated sutures reduce the risk of surgical site infections: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:169-179. 
  13. Chang WK, Srinivasa S, Morton R, et al. Triclosan-impregnated sutures to decrease. Surgical Site Infections: Systematic Review and Meta-Analysis of Randomized Trials. Ann Surg. 2012;255(5):854-859. 
  14. Daoud FC, Edmiston CE Jr, Leaper D. Meta-analysis of prevention of surgical site infections following incision closure with triclosan-coated sutures: robustness to new evidence. Surg Infect (Larchmt). 2014;15(3):165-181. 
  15. Daoud FC. Systematic literature review update of the PROUD Trial: potential usefulness of a collaborative database. Surg Infect (Larchmt). 2014;15(6):857-858. 
  16. Guo J, Pan LH, Li YX, et al. Efficacy of triclosan- coated sutures for reducing risk of surgical site infection in adults: a meta-analysis of randomized clinical trials. J Surg Res. 2016; 201(1):105-117. 
  17. Sajid MS, Craciunas L, Sains P, et al. Use of antibacterial sutures for skin closure in controlling surgical site infections: a systematic review of published randomized, controlled trials. Gastroenterol Rep (Oxf). 2013;1(1):42-50. 
  18. Sandini M, Mattavelli I, Nespoli L, Uggeri F, Gianotti L. Systematic review and meta-analysis of sutures coated with triclosan for the prevention of surgical site infection after elective colorectal surgery according to the PRISMA statement. Medicine (Baltimore). 2014;95(35):e4057. 
  19. Wang ZX, Jiang CP, Cao Y, et al. Systematic review and meta-analysis of triclosan-coated sutures for the prevention of surgical-site infection. Brit J Surg. 2013;100(4): 465-473. 
  20. Wu X, Kubilay NZ, Ren J, et al. Antimicrobial-coated sutures to decrease surgical site infections: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2017;36(1):19-32. 
  21. Ahmed I, Boulton AJ, Rizvi S, et al. The use of triclosan-coated sutures to prevent surgical site infections: a systematic review and meta-analysis of the literature. BMJ Open. 2019;9:e029727. doi:10.1136/ bmjopen-2019-029727. 
  22. Bhende S, Burkley D, Nawrocki J. In vivo and in vitro anti-bacterial efficacy of absorbable barbed polydioxanone monofilament tissue control device with triclosan. Surg Infect (Larchmt). 2018;19(4):430-437. 
  23. Kumar A. Completion Report for Design Verification testing for DERMABOND™ PRINEO™ 22 cm skin closure system (DP22) AST-2014-0060, Version 2. April 19, 2016. Ethicon, Inc. 
  24. DERMABOND® PRINEO® Skin Closure System [Instructions for Use], Ethicon, Inc. 
  25. Su W. Study Report for in vitro evaluation of microbial barrier properties of Dermabond® Protape. 06TR071. December 4, 2006. Ethicon, Inc. 
  26. Bhende S. In-vitro study to evaluate the ability of DERMABOND™ PRINEO™ Skin Closure System to kill bacteria on contact. June 22, 2012. Ethicon, Inc.
  27. Over 12 months as projected in a peer-reviewed economic analysis comparing triclosan-treated sutures and traditional wound closure methods. Median costs estimated to be avoided per patient for commercial payers and Medicare were $809 (95% CI, $26–$4481) and $870 (95% CI, $33–$4624), respectively.
  28. In a meta-analysis that included 21 RCTs, 6462 patients, 95% Cl: (14, 40%), P<0.001.
  29. All triclosan-coated sutures in these RCTs were Ethicon Plus Antibacterial Sutures (MONOCRYL® Plus Antibacterial (poliglecaprone 25) Suture, Coated VICRYL® Plus Antibacterial (polyglactin 910) Suture, and PDS® Plus Antibacterial (polydioxanone) Suture).
  30. Refers only to STRATAFIX'" Symmetric PDS™ Plus, STRATAFIX™ Spiral PDS™ Plus and STRATAFIX™ Spiral Monocryl™ Plus.
  31. Meta-analysis only included traditional (non-barbed) sutures.
  32. As seen in vitro.
  33. Clinical significance unknown.